Biotech Roundup: ASCO, BIO, Drug Setbacks, Incubators & More
Xconomy
JUNE 10, 2016
BIO president and CEO Jim Greenwood (pictured), a former Congressman-turned-lobbyist, told an audience, “We are fighting back,” and unveiled plans to put some of the blame for high drug prices on insurance companies. The new prices don’t reflect rebates and discounts.
Let's personalize your content